Meeting Report: American College of Cardiology 2014

APRIL 17, 2014
American College of Cardiology 2014
Washington, DC, March 29-31, 2014

More than 13,000 physicians and cardiovascular team members attended the ACC 2014 meeting in Washington, DC, to focus on the prevention, diagnosis, and treatment of cardiovascular disease.

In this issue of Cardiology Review, of the presentations made at ACC 2014 will be highlighted: SYMPLICITY HTN-3, MADIT-CRT, POISE-2, STAMPEDE, CHOICE, STABILITY, and DESCARTES.

Renal Denervation Does Not Reduce BP in Resistant Hypertension

SYMPLICITY HTN-3 principal investigators George Bakris, MD, and Deepak Bhatt, MD, announced at ACC 2014 that the phase III study of catheter-based renal denervation for the treatment of resistant hypertension did not achieve its primary or powered secondary efficacy end points, failing to show that treatment with the investigational procedure resulted in sustained reduction in systolic blood pressure. The trial is the first and only blinded, randomized, sham-controlled study of renal denervation for treatment-resistant hypertension. The study had randomized 535 patients with treatment-resistant hypertension in 87 US medical centers. Patients who received the investigational treatment were compared with a sham-control group that did not receive treatment; all patients continued to take their regular antihypertension medications.

The primary end point of the study was the change in office systolic blood pressure at 6 months, while the 6-month change in the average 24-hour systolic blood pressure assessed by ambulatory blood pressure monitoring was a secondary end point.

Medtronic, the sponsor of the Symplicity renal denervation system, noted that no safety issues arose during the trial. Data showed that the Symplicity system was associated with adverse events in less than 1% of patients, with no cases of renal artery stenosis resulting from the procedure.

The findings were surprising given that findings from the SYMPLICITY 2 study were positive. That study did not include a sham–control arm. The investigators are continuing to analyze the results and will be submitting them for publication.

Copyright© MD Magazine 2006-2020 Intellisphere, LLC. All Rights Reserved.